News

Inspira Technologies Secures Japanese Patent for Dual Lumen Device

Inspira Technologies Secures Japanese Patent for Dual Lumen Device

Inspira Technologies Achieves Patent Milestone in Japan

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), known for its pioneering advancements in life-support and diagnostic technologies, has reached an important milestone by securing a patent in Japan. The Japan Patent Office has granted Patent No. 7777598 for the innovative Convertible Dual Lumen Cannula device and its usage method. This achievement is significant as it solidifies the Company’s position within one of the leading markets for medical devices globally.

Exclusive Rights and Future Prospects

This new patent provides Inspira with exclusive commercial rights to its patented Dual Lumen Cannula technology in Japan until 2041. This development is a strategic addition to its existing U.S. Patent obtained earlier, creating a strong protective framework across two of the world’s largest healthcare economies. Such IP (intellectual property) protection is vital for Inspira’s plans regarding the standalone commercialization of its cannula, which is poised to become a high-demand disposable product in the market.

Innovative Design Benefits

The patented technology introduced by Inspira features a groundbreaking mechanism, enabling a single-lumen cannula to convert into a dual-lumen version after it has been inserted. This advancement is designed to allow healthcare professionals to switch configurations seamlessly during procedures, minimizing the need for further incisions. Such an approach can significantly lower infection rates, procedural complications, and can also lead to reduced costs for healthcare establishments compared to more traditional dual-lumen solutions.

Comments from Leadership

Dagi Ben-Noon, the CEO of Inspira Technologies, emphasized the substantial cost concerns associated with manufacturing traditional dual lumen cannulas. He noted, “Our patented convertible device introduces an economical solution for the market while potentially increasing patient safety and efficiency during procedures.” He also expressed confidence in the Company’s growth, highlighting the rigor of regulations in both Japan and the U.S., which bolster their business foundation despite challenging environments.

About Inspira Technologies

Inspira Technologies is a medical device company in the commercial stage, focusing on cutting-edge respiratory support and real-time blood monitoring solutions. The Company’s INSPIRA™ ART100 system holds FDA clearance for cardiopulmonary bypass procedures in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures internationally. The development of the INSPIRA ART500, a next-generation system that provides oxygenation while patients remain alert and capable of spontaneous breathing, further demonstrates Inspira’s commitment to innovation.

In addition to its core products, Inspira is also advancing the HYLA™ platform, which functions as a proprietary blood sensor for ongoing, non-invasive monitoring. With a growing portfolio of cleared devices, a solid intellectual property landscape, and a focus on refining operations, Inspira is increasingly recognized as a significant contender within the life-support and MedTech sectors.

Company Contact Information

Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Frequently Asked Questions

What is the significance of the patent granted to Inspira Technologies?

The patent secures exclusive commercial rights for their innovative Convertible Dual Lumen Cannula in Japan until 2041, enhancing their market position.

How does the Convertible Dual Lumen Cannula work?

It allows a single-lumen cannula to convert into a dual-lumen type after insertion, enabling healthcare professionals to switch configurations without additional incisions.

What are the advantages of this new technology?

This design potentially reduces infection risks, procedural complications, and hospital costs when compared to traditional dual-lumen options, making it more efficient and affordable.

How does this patent impact Inspira's future?

This exclusive patent positions Inspira to effectively commercialize its cannula technology independently and strengthens its revenue streams in targeted healthcare markets.

What other products does Inspira Technologies offer?

In addition to the dual lumen cannula, Inspira offers the INSPIRA™ ART100 and is developing the INSPIRA ART500 for advanced respiratory support, alongside its HYLA™ blood sensor platform.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 146

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 69

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 142

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 155

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 87

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 71

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 26

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 85

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 67

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Conagra Brands: Navigating Challenges with Strong Dividends and Growth

Updated Category News Views 164

Conagra's Market Position and Opportunities Conagra Brands Inc (NYSE: CAG) shares are currently experiencing a significant dip, providing a favorable opportunity for long-term investors to consider entry into the market. Despite the ongoing challenges that are affecting the consumer staples sector, Conagra has ended its recent business contraction. The company's...

Continue Reading
Unlocking the Potential of AeroVironment Stock Investments

Updated Category News Views 215

The Growth Journey of AeroVironment (NASDAQ: AVAV) AeroVironment continues to impress investors with its steady performance over recent years. This aerospace company specializes in drone technology and has showcased remarkable growth potential in a competitive industry. Despite the challenges posed by changing market conditions, AeroVironment has outperformed the market...

Continue Reading
Focal One® Robotic HIFU Shows Promise in Prostate Cancer Care

Updated Category News Views 131

Groundbreaking Results from the HIFI Study The HIFI Study stands as a significant milestone in the treatment of localized prostate cancer, presenting remarkable findings and setting the stage for a shift in medical practices. This extensive research, with a participant group of 3,328, compares HIFU treatment using Focal One® against traditional surgery methods,...

Continue Reading
VENU's Ambitious Growth Strategy Secures $34.5 Million Funding

Updated Category News Views 307

VENU Secures Funding to Propel Its Growth Strategy In recent news, VENU (NYSE American: VENU), a company leading the charge in premium hospitality and live entertainment, has successfully closed a public offering. This offering involved 2,875,000 shares of common stock, sold at a public price of $12.00 each, bringing in $34.5 million in gross proceeds. This substantial...

Continue Reading
Exploring Market Trends in the Food Colors Industry

Updated Category News Views 250

The food colors market saw a hefty rise, hitting projections of USD 6.0 billion by 2028 from USD 4.6 billion in 2023. This growth came at a compound annual growth rate (CAGR) of about 5.4%, thanks to shifting consumer preferences towards naturally sourced and visually appealing products. Market Dynamics: The Push for Natural Colors Back then, the processed food scene was...

Continue Reading